- Home
- JHS vs PLX Comparison
JHS vs PLX Comparison
Compare JHS & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JHS
- PLX
- Stock Information
- Founded
- JHS 1973
- PLX 1993
- Country
- JHS United States
- PLX United States
- Employees
- JHS N/A
- PLX N/A
- Industry
- JHS Finance Companies
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- JHS Finance
- PLX Health Care
- Exchange
- JHS Nasdaq
- PLX Nasdaq
- Market Cap
- JHS 131.4M
- PLX 127.4M
- IPO Year
- JHS N/A
- PLX 1998
- Fundamental
- Price
- JHS $11.46
- PLX $1.51
- Analyst Decision
- JHS
- PLX Strong Buy
- Analyst Count
- JHS 0
- PLX 1
- Target Price
- JHS N/A
- PLX $15.00
- AVG Volume (30 Days)
- JHS 32.8K
- PLX 539.9K
- Earning Date
- JHS 01-01-0001
- PLX 08-13-2025
- Dividend Yield
- JHS 3.96%
- PLX N/A
- EPS Growth
- JHS N/A
- PLX N/A
- EPS
- JHS 0.02
- PLX 0.05
- Revenue
- JHS N/A
- PLX $59,764,000.00
- Revenue This Year
- JHS N/A
- PLX $10.00
- Revenue Next Year
- JHS N/A
- PLX $83.13
- P/E Ratio
- JHS $553.50
- PLX $31.35
- Revenue Growth
- JHS N/A
- PLX 0.18
- 52 Week Low
- JHS $9.76
- PLX $0.82
- 52 Week High
- JHS $11.25
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- JHS 67.19
- PLX 50.83
- Support Level
- JHS $11.30
- PLX $1.41
- Resistance Level
- JHS $11.38
- PLX $1.52
- Average True Range (ATR)
- JHS 0.06
- PLX 0.07
- MACD
- JHS 0.01
- PLX 0.00
- Stochastic Oscillator
- JHS 87.54
- PLX 43.48
About JHS John Hancock Income Securities Trust
John Hancock Income Securities Trust is a United States-based closed-ended diversified management investment company. Its primary objective is to generate a high level of current income consistent with prudent investment risk. The fund invests its net assets (plus borrowings for investment purposes) in income securities, consisting of marketable corporate debt securities, governmental obligations, and cash and commercial paper. A majority of its net assets are invested in debt securities that are rated, at the time of acquisition, investment-grade or in unrated securities determined by the Fund's investment advisor or subadvisor to be of comparable credit quality.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.